Characterizing Antibody-Oligonucleotide Conjugates (AOCs) Under Native and Reversed-Phase Conditions
Antibody-oligonucleotide conjugates (AOCs) represent an emerging class of biotherapeutics that merge the precision and low toxicity of oligonucleotide drugs with the high specificity of antibodies. These conjugates typically consist of an antisense oligonucleotide (ASO) or siRNA linked to an antibody via cleavable or noncleavable linkers. Characterizing AOCs using liquid chromatography poses unique challenges, including sequence confirmation, oligonucleotide-to-antibody ratio (OAR) measurement, conjugation site identification, and impurity assessment. This webinar will showcase complementary LC-MS methods developed to characterize AOCs composed of a trastuzumab biosimilar conjugated with siRNA or ASO.
Key Learning Points
- Understand the structure of an antibody-oligo conjugate (AOC) and its components.
- Identify the analytical requirements and challenges of AOC characterization.
- Explore LC with MS and UV strategies for AOC characterization.
Who Should Attend
- Any scientists performing analytical LC method development for siRNA or ASO Oligo conjugate characterization
Speaker: Roxana Eggleston-Rangel (Senior Applications Scientist, Phenomenex)
Roxana joined Phenomenex in 2018 as an Applications Scientist and is currently working with the applications team to produce analytical solutions for the biopharma industry. Her current work focuses on characterization of mRNA, sgRNA and siRNA. Prior to Phenomenex, Roxana worked for Caltech and the University of Southern California developing LM-CS workflows for the proteomics community. She received her bachelor’s and master’s degree in Chemistry and Biochemistry from California State University, Los Angeles.
